The Phage Lysin PlySs2 Decolonizes Streptococcus suis from Murine Intranasal Mucosa.
Streptococcus suis infects pigs worldwide and may be zoonotically transmitted to humans with a mortality rate of up to 20%. S. suis has been shown to develop in vitro resistance to the two leading drugs of choice, penicillin and gentamicin. Because of this, we have pursued an alternative therapy to...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2017-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5207509?pdf=render |
id |
doaj-584db489c53d44668c9e774fe48e82ea |
---|---|
record_format |
Article |
spelling |
doaj-584db489c53d44668c9e774fe48e82ea2020-11-25T02:27:40ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-01121e016918010.1371/journal.pone.0169180The Phage Lysin PlySs2 Decolonizes Streptococcus suis from Murine Intranasal Mucosa.Daniel B GilmerJonathan E SchmitzMya ThandarChad W EulerVincent A FischettiStreptococcus suis infects pigs worldwide and may be zoonotically transmitted to humans with a mortality rate of up to 20%. S. suis has been shown to develop in vitro resistance to the two leading drugs of choice, penicillin and gentamicin. Because of this, we have pursued an alternative therapy to treat these pathogens using bacteriophage lysins. The bacteriophage lysin PlySs2 is derived from an S. suis phage and displays potent lytic activity against most strains of that species including serotypes 2 and 9. At 64 μg/ml, PlySs2 reduced multiple serotypes of S. suis by 5 to 6-logs within 1 hour in vitro and exhibited a minimum inhibitory concentration (MIC) of 32 μg/ml for a S. suis serotype 2 strain and 64 μg/ml for a serotype 9 strain. Using a single 0.1-mg dose, the colonizing S. suis serotype 9 strain was reduced from the murine intranasal mucosa by >4 logs; a 0.1-mg dose of gentamicin reduced S. suis by <3-logs. A combination of 0.05 mg PlySs2 + 0.05 mg gentamicin reduced S. suis by >5-logs. While resistance to gentamicin was induced after systematically increasing levels of gentamicin in an S. suis culture, the same protocol resulted in no observable resistance to PlySs2. Thus, PlySs2 has both broad and high killing activity against multiple serotypes and strains of S. suis, making it a possible tool in the control and prevention of S. suis infections in pigs and humans.http://europepmc.org/articles/PMC5207509?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Daniel B Gilmer Jonathan E Schmitz Mya Thandar Chad W Euler Vincent A Fischetti |
spellingShingle |
Daniel B Gilmer Jonathan E Schmitz Mya Thandar Chad W Euler Vincent A Fischetti The Phage Lysin PlySs2 Decolonizes Streptococcus suis from Murine Intranasal Mucosa. PLoS ONE |
author_facet |
Daniel B Gilmer Jonathan E Schmitz Mya Thandar Chad W Euler Vincent A Fischetti |
author_sort |
Daniel B Gilmer |
title |
The Phage Lysin PlySs2 Decolonizes Streptococcus suis from Murine Intranasal Mucosa. |
title_short |
The Phage Lysin PlySs2 Decolonizes Streptococcus suis from Murine Intranasal Mucosa. |
title_full |
The Phage Lysin PlySs2 Decolonizes Streptococcus suis from Murine Intranasal Mucosa. |
title_fullStr |
The Phage Lysin PlySs2 Decolonizes Streptococcus suis from Murine Intranasal Mucosa. |
title_full_unstemmed |
The Phage Lysin PlySs2 Decolonizes Streptococcus suis from Murine Intranasal Mucosa. |
title_sort |
phage lysin plyss2 decolonizes streptococcus suis from murine intranasal mucosa. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2017-01-01 |
description |
Streptococcus suis infects pigs worldwide and may be zoonotically transmitted to humans with a mortality rate of up to 20%. S. suis has been shown to develop in vitro resistance to the two leading drugs of choice, penicillin and gentamicin. Because of this, we have pursued an alternative therapy to treat these pathogens using bacteriophage lysins. The bacteriophage lysin PlySs2 is derived from an S. suis phage and displays potent lytic activity against most strains of that species including serotypes 2 and 9. At 64 μg/ml, PlySs2 reduced multiple serotypes of S. suis by 5 to 6-logs within 1 hour in vitro and exhibited a minimum inhibitory concentration (MIC) of 32 μg/ml for a S. suis serotype 2 strain and 64 μg/ml for a serotype 9 strain. Using a single 0.1-mg dose, the colonizing S. suis serotype 9 strain was reduced from the murine intranasal mucosa by >4 logs; a 0.1-mg dose of gentamicin reduced S. suis by <3-logs. A combination of 0.05 mg PlySs2 + 0.05 mg gentamicin reduced S. suis by >5-logs. While resistance to gentamicin was induced after systematically increasing levels of gentamicin in an S. suis culture, the same protocol resulted in no observable resistance to PlySs2. Thus, PlySs2 has both broad and high killing activity against multiple serotypes and strains of S. suis, making it a possible tool in the control and prevention of S. suis infections in pigs and humans. |
url |
http://europepmc.org/articles/PMC5207509?pdf=render |
work_keys_str_mv |
AT danielbgilmer thephagelysinplyss2decolonizesstreptococcussuisfrommurineintranasalmucosa AT jonathaneschmitz thephagelysinplyss2decolonizesstreptococcussuisfrommurineintranasalmucosa AT myathandar thephagelysinplyss2decolonizesstreptococcussuisfrommurineintranasalmucosa AT chadweuler thephagelysinplyss2decolonizesstreptococcussuisfrommurineintranasalmucosa AT vincentafischetti thephagelysinplyss2decolonizesstreptococcussuisfrommurineintranasalmucosa AT danielbgilmer phagelysinplyss2decolonizesstreptococcussuisfrommurineintranasalmucosa AT jonathaneschmitz phagelysinplyss2decolonizesstreptococcussuisfrommurineintranasalmucosa AT myathandar phagelysinplyss2decolonizesstreptococcussuisfrommurineintranasalmucosa AT chadweuler phagelysinplyss2decolonizesstreptococcussuisfrommurineintranasalmucosa AT vincentafischetti phagelysinplyss2decolonizesstreptococcussuisfrommurineintranasalmucosa |
_version_ |
1724841549393559552 |